/PRNewswire/ As per Facts and Factors study, The global physiotherapy equipment market size was worth around USD 19.05 billion in 2021 and is predicted to.
NEW YORK, Feb. 8, 2023 /PRNewswire/ As per Facts and Factors study, The global physiotherapy equipment market size was worth around USD 19.05 billion in 2021 and is predicted to grow to around
Washington University in St. Louis faculty from the McKelvey School of Engineering and the School of Medicine have been elected fellows of the National Academy of Inventors.
Innovative multidisciplinary research at Washington University led to development of breakthrough device
Eric Leuthardt, MD, professor of neurosurgery at Washington University School of Medicine, models a device that helps people disabled by stroke regain significant control over their arm and hand function by using their minds. Called the IpsiHand Upper Extremity Rehabilitation System, the first-of-its-kind device has received market authorization from the Food and Drug Administration. It was developed by Neurolutions Inc., a Washington University startup company that leverages brain-computer interface technology licensed from the university. (Photo: Elizabethe Holland Durando/School of Medicine)
April 27, 2021 SHARE
A first-of-its kind device that helps people disabled by stroke regain significant control over their arm and hand function by using their minds has received market authorization from the Food and Drug Administration (FDA). The IpsiHand Upper Extremity Rehabil
Neurolutions Receives U.S. Food and Drug Administration De Novo Market Authorization for IpsiHand™ Upper Extremity Rehabilitation System
April 26, 2021 07:00 ET | Source: Neurolutions Neurolutions
IpsiHand also has been granted U.S. FDA Breakthrough Device Designation
SANTA CRUZ, Calif. and ST. LOUIS, Mo., April 26, 2021 (GLOBE NEWSWIRE) Neurolutions, Inc., a medical device company developing and commercializing a first-of-its-kind device leveraging brain-computer interface (BCI) technology for upper extremity chronic stroke rehabilitation, announced today that the U.S. Food and Drug Administration (FDA) granted De Novo market authorization for its groundbreaking IpsiHand Upper Extremity Rehabilitation System. The IpsiHand System has been cleared for use in chronic stroke patients to facilitate muscle re-education through its novel BCI platform. In addition to the De Novo Authorization, the IpsiHand device notably received Breakthrough Device